(Press-News.org) From today (1 July 2015) The BMJ requires sharing of individual patient data for all clinical trials.
This means that trials will be considered for publication only if the authors agree to make the relevant anonymised patient level data available on reasonable request.
The BMJ is the first general medical journal to require data sharing for all trials, extending its initial policy on sharing data for trials of drugs or devices, which took effect in January 2013, says Elizabeth Loder, The BMJ's acting head of research.
In an editorial to mark the launch of the new policy, she explains that the initial policy focused on trials of drug and devices "because many high profile, serious allegations of selective or non-reporting of trial results related to such products."
However, she says, growing experience and evidence show that reporting problems are not limited to the corporate sector, but affect academic and government sponsored trials as well. And she points out that, "to date, all authors have agreed, and we have not rejected a single paper for non-compliance."
Today's announcement follows initiatives by the US Institute of Medicine (IOM), the World Health Organization (WHO), and the Nordic Trial Alliance, to encourage data transparency.
For example, a recent IOM report called for a transformation of existing scientific culture to one where "data sharing is the expected norm" while WHO has said the main results of clinical trials should be made publicly available and submitted for journal publication within a year of study completion.
The efforts of industry, too, must be acknowledged, says Loder. In particular, Medtronic's cooperation with the Yale University Open Data project and GlaxoSmithKline's leadership on data disclosure efforts stand out.
"Making anonymised patient level data from clinical trials available for independent scrutiny allows other researchers to replicate key analyses, reduces the possibility that studies will be unnecessarily duplicated, and maximises use of the information from trials - an important moral obligation to trial participants," she writes.
She acknowledges that an initial investment of time and money is needed to prepare trial data for sharing, "but after the first use there are few additional costs; in essence, the value of the data increases with each use," she concludes.
INFORMATION:
The stress hormone cortisol strengthens memories of scary experiences. However, it is effective not only while the memory is being formed for the first time, but also later when people look back at an experience while the memory reconsolidates. This has been published by cognition psychologists from the Ruhr-Universität Bochum in the journal "Neuropsychopharmacology". They suggest that the results might explain the persistence of strong emotional memories occurring in anxiety and Post-Traumatic Stress Disorder (PTSD).
Memories of emotional experiences usually fade ...
Thin fibers play a tremendous role in many areas of our daily life, from the use of glass fibers in ultra-fast data transmission to textile fibers in our clothing. In order to enable special properties of these fibers, they are often coated with a thin liquid layer that is supposed to be stable and homogeneous. However, for the production of drinkable water, the exact opposite features are desired: there, one aims at harvesting water, which is transported along the fiber as a liquid film or as liquid droplets, from fog. Now, scientists have been able to reveal, by means ...
This news release is available in German. Observing time at the European Southern Observatory (ESO) on Paranal Mountain is a very precious commodity - and yet the Very Large Telescope (VLT) in Chile spent an entire night with a high-resolution infrared camera pointed at a single object in the night sky. The data collected by the Naco optics instrument enabled an international team headed by ETH Zurich's Sascha Quanz to confirm its earlier hypothesis: that a young gas planet - presumed not unlike Jupiter in our own solar system - is orbiting the star designated HD 100546.
At ...
This news release is available in German.
A new bio-inspired zeolite catalyst, developed by an international team with researchers from Technische Universität München (TUM), Eindhoven University of Technology and University of Amsterdam, might pave the way to small scale 'gas-to-liquid' technologies converting natural gas to fuels and starting materials for the chemical industry. Investigating the mechanism of the selective oxidation of methane to methanol they identified a trinuclear copper-oxo-cluster as the active center inside the zeolite micropores.
In ...
Being busy with acts of kindness can help people who suffer from social anxiety to mingle more easily. This is the opinion of Canadian researchers Jennifer Trew of Simon Fraser University and Lynn Alden of the University of British Columbia, in a study published in Springer's journal Motivation and Emotion.
Sufferers from social anxiety are more than just a little shy. Dealings with others might make them feel so threatened or anxious that they often actively avoid socializing. Although this protects them from angst and possible embarrassment, they lose out on the support ...
More than one in ten complaints of sexual harassment at work are reported by men, a QUT study has found.
According to the research, conducted by Professor Paula McDonald from the QUT Business School and Professor Sara Charlesworth from RMIT, women were accused of sexually harassing men in 5 per cent of cases and men accused other men in 11 per cent of cases.
Workplace sexual harassment at the margins, published in the Work, Employment and Society journal, analysed sexual harassment complaints lodged with Australian equal opportunity commissions in the six months from ...
BARCELONA-LUGANO, 1 July 2015 - The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.
Roila's comments came as the SENRI Trial results were presented including a new gender analysis (1),(2). He said: "Until now we said that NK1 antagonists have no role in the prevention of emesis in ...
BARCELONA-LUGANO, 1 July 2015 - Patients with the lowest body mass index (BMI) had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer (mCRC) presented for the first time today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.(1)
"There is good evidence that obesity increases the risk of getting colorectal cancer and that it increases the risk of colorectal cancer recurrence after curative therapy," said lead study author Dr Yousuf Zafar, associate professor of medicine at Duke Cancer Institute ...
DURHAM, N.C. - Although being overweight with a high body-mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.
The study, which was presented today at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, found that patients with a low to healthy body weight lived an average of two-and-a-half months less than overweight and obese patients.
The results surprised researchers, who expected ...
Lexington, Mass., July 1, 2015 - Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products. The deuterium chemistry approach has the potential to reduce the high failure rates of conventional drug development by building on the known pharmacology of existing compounds and leveraging their desirable therapeutic properties. Selective deuterium substitution as a means of ameliorating unwanted clinically ...
